Papers
11
Total Citations
74
H-Index
6
About
Sergi Vidal‐Sicart is a leading figure in interventional nuclear medicine and radioguided surgery, with a career dedicated to advancing molecularly targeted precision surgery. His research focuses on the development and clinical translation of novel radioguidance technologies, particularly for prostate and gynecological cancers. Vidal‐Sicart has been instrumental in introducing the tethered DROP-IN gamma probe, a steerable device that has revolutionized minimally invasive, robot-assisted sentinel lymph node (SLN) dissection. His work demonstrates how this tool enhances surgical precision in both PSMA-targeted prostate cancer resection and cervical/endometrial cancer procedures, enabling real-time, image-guided tumor localization. With over 80 citations across his most influential papers, his contributions have shaped international consensus on SLN mapping in head and neck and gynecological tumors. Notably, his 2023 multicenter trial validated the DROP-IN probe’s clinical efficacy, while his comprehensive reviews have set standards for integrating molecular imaging into surgery. Vidal‐Sicart’s research bridges nuclear medicine and surgical oncology, offering trainees a clear vision of how interventional nuclear medicine can transform patient outcomes through targeted, minimally invasive approaches.
Research Focus
Key Achievements
Top Papers
- 1
- 2Molecular image–guided surgery in gynaecological cancer: where do we stand?12 citations · 2024
- 3New devices in radioguided surgery10 citations · 2023
- 4Sentinel node approach in prostate cancer7 citations · 2015
- 5
- 6
- 7
- 8
- 9
- 10Sentinel node approach in prostate cancer2 citations · 2015